NasdaqHealth CareHealth Care EquipmentS&P MidCap 400
$89.99
-1.15 (-1.26%)
Close of Nov 06, 2026 · end-of-day data
LIVN 8-K filings in 2025
Every material Form 8-K LivaNova filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LivaNova reported third-quarter 2025 revenue of $357.8 million, up 12.5% from a year earlier, and raised its full-year 2025 adjusted diluted EPS guidance to $3.80 to $3.90. GAAP diluted EPS fell to $0.49 from $0.60, and the nine-month GAAP net loss of $273.4 million reflects a $363.8 million SNIA environmental liability expense.
Q3 2025 revenue $357.8 million vs $318.1 million a year earlier
Q3 GAAP diluted EPS $0.49 vs $0.60; adjusted diluted EPS $1.11 vs $0.90
2025 adjusted diluted EPS guidance raised to $3.80 to $3.90 from $3.70 to $3.80
Nine-month GAAP net loss $273.4 million, including $363.8 million SNIA environmental liability expense
LivaNova's board appointed Donald Zurbay, former CEO and CFO of Patterson Companies, as a director effective September 4, 2025, and as a member of the Audit and Compliance Committee. The filing describes his prior roles at Patterson Companies and St. Jude Medical and lists his director compensation, which is prorated until the 2026 Annual General Meeting.
Donald Zurbay joins the board and Audit and Compliance Committee; his term begins September 4, 2025.
He was President and CEO of Patterson Companies from October 2022 until May 2025, and its CFO from June 2018 to October 2022.
Annual compensation includes a $70,000 board retainer, a $15,000 committee member fee, and restricted stock with a fair market value of $185,000, prorated to the 2026 Annual General Meeting.
LivaNova reported second-quarter 2025 revenue of $352.5 million, up 10.7% from a year earlier, and raised its full-year 2025 guidance for revenue growth, adjusted diluted earnings per share and adjusted free cash flow. Adjusted diluted earnings per share were $1.05 for the quarter, compared with $0.93 a year earlier, and GAAP diluted earnings per share were $0.50, compared with $0.30. The results were furnished as Exhibit 99.1 and the company will discuss them on a conference call on August 6, 2025.
Q2 2025 revenue was $352.5 million, up 10.7% on a reported basis and 10.3% on an organic basis.
Q2 2025 GAAP diluted EPS was $0.50 versus $0.30; adjusted diluted EPS was $1.05 versus $0.93.
Full-year 2025 adjusted diluted EPS guidance rose to $3.70 to $3.80 from $3.60 to $3.70.
Full-year 2025 adjusted free cash flow guidance is $140 million to $160 million, up from $135 million to $155 million.
At its 2025 Annual General Meeting on June 11, 2025, LivaNova shareholders adopted all 12 resolutions, including approval of the Second Amended and Restated 2022 Incentive Award Plan and the 2025 Director Incentive Award Plan. The filing says the 2022 plan provides 2,200,000 shares for awards and the director plan makes 300,000 shares available, with no further awards to be made under the 2015 Plan. Shareholders should note that these approvals set the share reserves for future equity compensation.
Second A&R 2022 Plan provides for 2,200,000 shares; approved with 43,306,724 votes for and 1,200,919 against.
2025 Director Incentive Plan makes 300,000 shares available to non-executive directors; approved with 44,032,808 votes for and 488,643 against.
All ten directors were elected for terms expiring at the 2026 AGM; advisory say-on-pay vote passed with 43,157,281 votes for and 1,352,691 against.
A total of 46,359,157 shares, about 83.59% of shares outstanding and eligible to vote, were represented at the meeting.
LivaNova reported first-quarter 2025 revenue of $316.9 million, up 7.4% from a year earlier, and raised its full-year revenue growth guidance. The company also recorded a $360.4 million SNIA environmental liability after an Italian Supreme Court ruling, producing a U.S. GAAP diluted loss of $6.01 per share, and lowered its full-year adjusted diluted EPS guidance to $3.60 to $3.70 from $3.65 to $3.75.
Q1 2025 revenue $316.9 million, up 7.4% reported and 10.4% organic; Cardiopulmonary revenue rose 13.1%
GAAP diluted loss of $6.01 per share versus $0.78 loss a year earlier, driven by the SNIA environmental liability; adjusted diluted EPS $0.88 versus $0.73
Full-year 2025 revenue growth guidance raised to 6.0% to 7.0% constant-currency; adjusted diluted EPS guidance lowered to $3.60 to $3.70, incorporating an estimated $0.20 SNIA impact
Adjusted free cash flow guidance unchanged at $135 million to $155 million
LivaNova reported fourth-quarter revenue of $321.8 million, up 3.8%, and full-year 2024 revenue of $1.25 billion, up 8.7%. Full-year 2024 adjusted diluted EPS was $3.38, up from $2.80, and the company guided to 2025 adjusted diluted EPS of $3.65 to $3.75, which is above the 2024 figure.
Q4 2024 revenue $321.8 million, up 3.8% reported; GAAP diluted EPS $1.02 versus $0.30; adjusted diluted EPS $0.81 versus $0.87
Full-year 2024 revenue $1.25 billion, up 8.7%; GAAP diluted EPS $1.16; adjusted diluted EPS $3.38 versus $2.80
2025 guidance: revenue growth of 5.0% to 6.0% on a constant-currency basis; adjusted free cash flow of $135 million to $155 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LivaNova filing is on SEC EDGAR ↗. 8-K briefs of other companies →